This scholarship page was last updated on 24 August 2023. Some details may have changed since then. Please check the Department of Health and Human Services National Institutes of Health website or the Department of Health and Human Services National Institutes of Health page for current opportunities.

Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed)

Department of Health and Human Services National Institutes of Health

Type

Research/project funding

Posted on:

24 August 2023

Date limite d´inscription:

Expired

Reference Number

RFA-AG-24-046

This Notice of Funding Opportunity (NOFO) aims toprovide a proof-of-principle for a novel strategy for Alzheimer Disease and Alzheimer Related Dementias (AD/ADRD) immunotherapies. Specifically, the goal is to examine if a novel immunotherapeutic approach in cancer immunotherapy with Chimeric Antigen Receptor (CAR) immune cellscould be customized as treatments for AD/ADRD. This NOFO utilizes the R61/R33Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities.
Categories: Health.

More Information

Visit Website